β-肾上腺素能受体作为眼部肿瘤和其他眼病的治疗靶点：历史方面和现今的认识。

β-Adrenoreceptors as Therapeutic Targets for Ocular Tumors and Other Eye Diseases-Historical Aspects and Nowadays Understanding.

机构信息

Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany.

出版信息

Int J Mol Sci. 2023 Feb 28;24(5):4698. doi: 10.3390/ijms24054698.

DOI:10.3390/ijms24054698

PMID:36902129

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10003534/

Abstract

β-adrenoreceptors (ARs) are members of the superfamily of G-protein-coupled receptors (GPCRs), and are activated by catecholamines, such as epinephrine and norepinephrine. Three subtypes of β-ARs (β, β, and β) have been identified with different distributions among ocular tissues. Importantly, β-ARs are an established target in the treatment of glaucoma. Moreover, β-adrenergic signaling has been associated with the development and progression of various tumor types. Hence, β-ARs are a potential therapeutic target for ocular neoplasms, such as ocular hemangioma and uveal melanoma. This review aims to discuss the expression and function of individual β-AR subtypes in ocular structures, as well as their role in the treatment of ocular diseases, including ocular tumors.

摘要

β-肾上腺素受体（ARs）是 G 蛋白偶联受体（GPCRs）超家族的成员，由儿茶酚胺（如肾上腺素和去甲肾上腺素）激活。已经鉴定出三种β-AR 亚型（β、β 和β），它们在眼部组织中的分布不同。重要的是，β-ARs 是治疗青光眼的既定靶点。此外，β-肾上腺素能信号与各种肿瘤类型的发展和进展有关。因此，β-ARs 是眼部肿瘤（如眼部血管瘤和葡萄膜黑色素瘤）的潜在治疗靶点。本综述旨在讨论各个β-AR 亚型在眼部结构中的表达和功能，以及它们在治疗眼部疾病（包括眼部肿瘤）中的作用。